GCL
SNTI icon

Glazer Capital LLC’s Senti Biosciences Holdings SNTI Stock Holding History

Glazer Capital LLC’s Portfolio SNTI Stock Details SNTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,176
Closed -$216K – 979
2021
Q2 		$216K Buy
+2,176
New +$217K ﹤0.01% 731

Other funds holding SNTI

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
DCP
D1 Capital Partners New York $11.2B AUM 15.78% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Glazer Capital LLC's SNTI Position: Q3 2021 in Review

Glazer Capital LLC sold out of Senti Biosciences Holdings (SNTI) in Q3 2021, closing a stake of 2,176 shares — an estimated $216K sold.

Glazer Capital LLC first reported a position in SNTI in Q2 2021 and held it in 1 quarter. The position peaked at $216K in Q2 2021. 39 funds tracked by Wall St. Rank hold SNTI as of Q3 2021.

  • Glazer Capital LLC reported no remaining Senti Biosciences Holdings position as of Q3 2021 after selling out during the quarter.
  • Glazer Capital LLC sold 2,176 Senti Biosciences Holdings shares in Q3 2021, an estimated $216K.
  • Glazer Capital LLC first reported a position in Senti Biosciences Holdings in Q2 2021 and held it in 1 quarter.
  • Glazer Capital LLC's Senti Biosciences Holdings position peaked at $216K in Q2 2021.
  • 39 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q3 2021.

Based on Glazer Capital LLC's 13F filing for Q3 2021, filed 15 Nov 2021.